PepGen (PEPG) investor relations material

Company overview and business model

• Clinical-stage biotechnology company focused on oligonucleotide therapeutics for severe neuromuscular and neurologic diseases.

• Proprietary Enhanced Delivery Oligonucleotide (EDO) platform uses cell-penetrating peptides to improve uptake and activity of therapeutics.

• Lead program targets myotonic dystrophy type 1 (DM1), a disease with high unmet need and no approved therapies.

• Extensive preclinical studies support the clinical development plan for the lead candidate PGN-EDODM1.

• Incorporated in Delaware, completed IPO in May 2022, and listed on Nasdaq under ticker “PEPG.”

Financial performance and metrics

• As of May 15, 2026, 69,169,215 shares of common stock outstanding; no preferred stock outstanding.

• Up to $400 million in securities may be offered, including $100 million in common stock via at-the-market (ATM) sales.

• Closing price of common stock on May 15, 2026, was $1.55 per share.

• Financial statements for 2025 and 2024 audited by KPMG LLP and incorporated by reference.

Use of proceeds and capital allocation

• Net proceeds intended for general corporate purposes, including R&D, clinical development, working capital, capital expenditures, and administrative expenses.

• May use a portion of proceeds to in-license, acquire, or invest in complementary businesses or technologies.

• Pending use, proceeds may be invested in high-quality, investment-grade instruments or held as cash.

• Management retains broad discretion over allocation of net proceeds.